Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Biofilms of Mycobacterium abscessus complex can be sensitized to antibiotics by disaggregation and oxygenation

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Extracellular Polysaccharide Matrix of Pseudomonas aeruginosa Biofilms Is a Determinant of Polymorphonuclear Leukocyte Responses

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Antibiotic susceptibility of cystic fibrosis lung microbiome members in a multispecies biofilm

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Bacterial aggregate size determines phagocytosis efficiency of polymorphonuclear leukocytes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Pulmonary infection with the multidrug-resistant Mycobacterium abscessus complex (MABSC) is difficult to treat in individuals with cystic fibrosis (CF). MABSC grows as biofilm aggregates in CF patient lungs, which are known to have anaerobic niches. How aggregation and anoxic conditions affect antibiotic tolerance is not well understood. We sought to determine whether disaggregation and oxygen availability sensitize MABSC isolates to recommended antibiotics. We tested the susceptibilities of 33 isolates from 22 CF patients with MABSC infection and a reference strain to the following antibiotics: amikacin, azithromycin, cefoxitin, ciprofloxacin, clarithromycin, imipenem, kanamycin, linezolid, moxifloxacin, rifampin, tigecycline, and sulfamethoxazole-trimethoprim. Isolates were grown in Mueller-Hinton broth with and without the disaggregating detergent Tween 80 (5%). Time-kill curves at days 1 and 3 were generated for oxic and anoxic amikacin treatment in 4-fold dilutions ranging from 2 to 512 mg liter -1 Scanning electron microscopy was used to visualize the aggregation patterns, while confocal laser scanning microscopy and microrespirometry were used to visualize biofilm growth patterns. Disruption of MABSC aggregates increased susceptibility to amikacin, tigecycline, kanamycin, azithromycin, imipenem, cefoxitin, and clarithromycin ( P  < 0.05, n  = 29 to 31). Oxygenation enhanced the killing of disaggregated MABSC isolates by amikacin ( P  < 0.05) by 1 to 6 log units when 2 to 512 mg liter -1 of amikacin was used. This study explains why current drug susceptibility testing results correlate poorly with treatment outcomes. The conditions achieved by oxic culturing of planktonic isolates in vitro do not resemble the hypoxic conditions in CF patient lungs. Biofilm disruption and increased O 2 availability during antibiotic therapy may be new therapeutic strategies for chronic MABSC infection.

Original languageEnglish
JournalAntimicrobial Agents and Chemotherapy
Volume64
Issue number2
Pages (from-to)e01212-19
Number of pages13
ISSN0066-4804
DOIs
Publication statusPublished - 27 Jan 2020

Bibliographical note

Copyright © 2020 American Society for Microbiology.

    Research areas

  • Antimicrobial resistance, Biofilm, Cystic fibrosis, Mycobacterium abscessus complex, Oxygenation, Aerobiosis, Cystic Fibrosis/complications, Biofilms/drug effects, Humans, Oxygen/pharmacology, Male, Anti-Bacterial Agents/pharmacology, Microbial Sensitivity Tests, Young Adult, Polysorbates/pharmacology, Drug Resistance, Multiple, Bacterial, Mycobacterium Infections, Nontuberculous/drug therapy, Adolescent, Female, Lung/microbiology, Child, Surface-Active Agents/pharmacology, Mycobacterium abscessus/drug effects, oxygenation, antimicrobial resistance, cystic fibrosis, biofilm

ID: 58993453